லாரன்ஸ் கிலோட்ஜ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லாரன்ஸ் கிலோட்ஜ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லாரன்ஸ் கிலோட்ஜ Today - Breaking & Trending Today

Educational opportunities on September 29 upcoming

Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) The earlier program that evening is being coordinated by the… ....

United States , Elisabeth Heath , Laurence Klotz , Wayne State University , Cancer Support Community Of Greater Cincinnati , Prostate Cancer International , Karamanos Cancer Center , Sunnybrook Health Sciences Center , Cancer Support Community , Greater Cincinnati , Northern Kentucky , Prostate Cancer , ஒன்றுபட்டது மாநிலங்களில் , எலிசபெத் ஹீத் , லாரன்ஸ் கிலோட்ஜ , வேன் நிலை பல்கலைக்கழகம் , ப்ராஸ்டேட் புற்றுநோய் சர்வதேச , சன்னிபிரூக் ஆரோக்கியம் அறிவியல் மையம் , புற்றுநோய் ஆதரவு சமூக , அதிகமானது ஸிந்ஸந்யாடீ , வடக்கு கெந்‌டகீ , ப்ராஸ்டேட் புற்றுநோய் ,

MRI-targeted biopsy shows value in prostate cancer

February 5, 2021 Multiparametric MRI-targeted biopsy for clinically significant prostate cancer can yield detection rates similar to systematic transrectal ultrasound-guided (TRUS) biopsy, while potentially enabling over one-third of prostate biopsies to be avoided, according to research published online February 4 in
In a multicenter, prospective, and randomized phase III study called PRostate Evaluation for Clinically Important Disease: MRI vs. Standard Evaluation Procedures (PRECISE), a team of researchers from Canada found that providing targeted biopsies after a positive multiparametric MRI scan was noninferior to systematic TRUS biopsies for detecting prostate cancers with an International Society of Urological Pathology grade group (GG) of 2 or higher. ....

Laurence Klotz , Olivier Rouvi , International Society Of Urological Pathology , Sunnybrook Health Sciences Center , Clinically Important Disease , Evaluation Procedures , International Society , Urological Pathology , Medical Imaging , Multiparametric Mri , Transrectal Ultrasound , Targeted Biopsy , லாரன்ஸ் கிலோட்ஜ , சர்வதேச சமூகம் ஆஃப் சிறுநீரக நோயியல் , சன்னிபிரூக் ஆரோக்கியம் அறிவியல் மையம் , மருத்துவ ரீதியாக முக்கியமான நோய் , மதிப்பீடு ப்ரொஸீஜர்ஸ் , சர்வதேச சமூகம் , சிறுநீரக நோயியல் , மருத்துவ இமேஜிங் , இலக்கு பயாப்ஸி ,

LIDDS AB: European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca Depot

(1)
UPPSALA, SWEDEN - LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid as being an innovative technology platform, said Monica Wallter, CEO of LIDDS.
Liproca Depot, which comprises the NanoZolid technology combined with an antiandrogen drug (2-hydroxyflutamide) injected into the prostate, met both the primary and secondary endpoints in the study. Efficacy was shown by a maintained PSA decrease over 6 months, lower prostate volume and unchanged or improved MRI results. No hormonal side effects were shown. L ....

Uppsala Lan , Laurence Klotz , Monica Wallter , University Of Toronto Division Urology , European Urology Focus , Liproca Depot , Professor Laurence Klotz , Toronto Division , லாரன்ஸ் கிலோட்ஜ , பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் , ஐரோப்பிய சிறுநீரகம் கவனம் , ப்ரொஃபெஸர் லாரன்ஸ் கிலோட்ஜ , டொராண்டோ பிரிவு ,

Another Win for MRI and Targeted Prostate Biopsy

email article
Prostate MRI followed by selective biopsy detected as many clinically significant cancers as standard ultrasound-guided systematic biopsy and detected 50% fewer low-risk cancers, a large randomized trial showed.
Targeted biopsy with multiparametric MRI identified grade group (GG) ≥2 tumors in 35% of men as compared with 30% for systematic biopsy with transrectal ultrasound (TRUS) guidance. The proportion of GG1 tumors decreased from 22% with TRUS biopsy (Bx) to 10% with targeted MRI-guided biopsy. Almost 40% of men randomized to the MRI group had negative imaging results, allowing them to avoid biopsy altogether.
Men who had MRI-guided prostate biopsy also had fewer adverse events (AEs), Laurence Klotz, MD, of the Sunnybrook Health Sciences Center in Toronto, and coauthors reported in ....

Laurence Klotz , Olivier Rouvi , Charles Bankhead , University Of Lyon , Sunnybrook Health Sciences Center , Ideal Pathway Not , Prostate Cancer Prevention Trial Risk , Medpage Today , லாரன்ஸ் கிலோட்ஜ , சார்லஸ் வங்கித் தலை , பல்கலைக்கழகம் ஆஃப் லியோன் , சன்னிபிரூக் ஆரோக்கியம் அறிவியல் மையம் , ஏற்றதாக நடைபாதை இல்லை , ப்ராஸ்டேட் புற்றுநோய் ப்ரெவெந்ஶந் சோதனை ஆபத்து ,

Investegate |LIDDS AB Announcements | LIDDS AB: European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot

LIDDS AB
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
“We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid® as being an innovative technology platform,” said Monica Wallter, CEO of LIDDS. ....

Uppsala Lan , Laurence Klotz , Monica Wallter , University Of Toronto Division Urology , European Urology Focus , Liproca Depot , Professor Laurence Klotz , Toronto Division , Nasdaq First North , Certified Adviser , லாரன்ஸ் கிலோட்ஜ , பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் , ஐரோப்பிய சிறுநீரகம் கவனம் , ப்ரொஃபெஸர் லாரன்ஸ் கிலோட்ஜ , டொராண்டோ பிரிவு , நாஸ்டாக் முதல் வடக்கு ,